Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will report fourth quarter and full year 2019 financial results on Wednesday, February 26, 2020 after the market close.
Alimera Sciences, Inc. (ALIM), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has appointed Steven T. Gill as Vice President, Thought Leader Engagement. Mr. Gill rejoins Alimera from Novartis US where he was Associate Director, Thought Leader Liaison. In this newly created position at Alimera, Mr. Gill will have the responsibility to advocate for Alimera with physician and professional societies, further driving Alimera’s mission to be invaluable to patients, physicians and partners concerned with retinal health.
Q1 2020 Alimera Sciences Inc Earnings Call
The psychology of investing presents an interesting conundrum. When a stock soars, the natural tendency is to want to get in on the action, as the FOMO kicks in and the allure of further gains is hard to resist. This is often the wrong choice as the stock will likely be sold off at a premium to latecomers.Conversely, a beaten-down stock induces tremors of fear. The inevitable concern about the stock’s low valuation and negative market sentiment can cause potential investors to avoid backing what appears to be a losing horse. This is sometimes the case, but other times share price weakness represents the best time to get in before a stock sets off on its upward trajectory.So how can you tell the losers from the winners? While nothing is certain, the experts on Wall Street can lend a helping hand. In a recent note to clients, B. Riley FBR analyst Andrew D’Silva highlights stocks in the healthcare sector which he thinks are set to make headway in 2020.“Each company either exited 2019 on a strong footing, where momentum is poised to carry over into 2020, or has fallen out of favor, but execution will result in a reversal,” the analyst commented.Using TipRanks’ Stock Comparison tool, we were able to zoom in on 2 of D’Silva’s choices. Whether beaten-down or flying high, all have plenty of room for upside, and all currently have a Strong Buy consensus rating from the Street. Let's take a closer look:Alimera Sciences (ALIM)Alimera Sciences had a miserable 2019. The retinal disease focused company lost 30% of its share price over the year. So far, 2020 has not been kinder, either. The share price is down by almost 10% year-to-date.So, should investors stay away? Absolutely not, says D’Silva. Now is the time to reassess the biopharma’s potential.The drop, he says, was instigated by the significant impact of 2Q19 results missing expectations, which were mostly attributed to a significant loss of domestic sales force. During 1H19, “several companies launched ophthalmic offerings and established/expanded their sales teams.” The numerous employment opportunities contributed to a depletion of Alimera’s own sales team.“We believe this compounded investor working capital concerns, as ALIM's $40 million term loan's interest-only period was scheduled to end within a year's time,” D’Silva noted.However, the analyst expects a “significant reversal this year.” He cited a resolution to the company’s sales force turnover issues, an expanding international footprint, and the “significant milestone” of management’s positive 2020 adjusted EBITDA guidance as reasons for the anticipated turnaround. Furthermore, a new debt refinancing arrangement “cleared a significant working capital overhang.”D’Silva noted, “While we expected that the company would refinance its term loan, we believe this should remove a significant trading overhang related to investor fears that ALIM would need to raise capital through a highly dilutive equity financing to fund operations and meet its debt obligation.”D'Silva, therefore, reiterated a Buy rating on Alimera along with a price target of $24. With ALIM currently trading at $6.91, the upside potential comes in at a massive 243%. (To watch D’Silva’s track record, click here)All in all, three analysts are currently keeping track of the eye disease specialist and all three see better days ahead too, rating the stock a Buy. With an average price target of $20.50, the figure suggests potential upside of nearly 200%. (See Alimera price targets and analyst ratings on TipRanks)CytoSorbents Corporation (CTSO)In a similar vein to Alimera, CytoSorbents is a beaten-down stock, displaying even further wreckage. It lost 52% of its share price during last year’s bull run.CTSO’s blood purification technologies are used to control deadly inflammation in critically-ill and cardiac surgery patients. After exhibiting revenue growth of 51% in 2018, the growth curve slowed down to 9% year-over-year in the first three quarters of 2019.D’Silva explained, “While the slower top-line growth could be concerning at first glance, the two primary reasons for the slowdown were related to two CS distributors and Fresenius Medical Care—which, together, accounted for ~15%-20% of the CTSO top line in 2018—entering 2019 with excess inventory, as well as CTSO running into sales-force bandwidth issues in its largest market, Germany.”With CTSO commencing sales in Poland, Sweden, Denmark, Norway, and the Netherlands, D’Silva foresees a turnaround in the months ahead.“While we don't anticipate CTSO realized significant benefits from new direct sales regions in 4Q19, as most new sales hires were onboarded in 2H19, we do expect CTSO's expanded footprint to provide a significant benefit this year… Meanwhile, We believe there are numerous clinical and regulatory catalysts are on the horizon that should be significant value drivers for the stock if successful,” said the analyst.As a result, D’Silva kept his Buy rating and supports it with an ambitious $12 price target. Attaining this number will provide a very healthy 210% gain in the next twelve months.Does the Street agree? Those who are taking notice certainly do. 3 Buy ratings and no Holds or Sells add up to a unanimous Strong Buy consensus rating. The recommendation comes alongside an average price target of $11 and implies upside potential of 176%. (See CytoSorbents stock-price forecast and analyst ratings)
Alimera Sciences, Inc. (ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announces it received on April 22, 2020 approximately $1.8 million in support from the federal government under the Paycheck Protection Program (PPP). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (CARES Act), provides for loans to qualifying businesses for amounts up to 2.5 times the average monthly U.S. payroll costs of the qualifying business, calculated as provided under the PPP.
Fourth Quarter Highlights: Consolidated Net Revenue of $17.3 Million; Up 15% Over Q4 2018International Net Revenue Up 26% Compared to Q4 2018Net Income of $498,000 vs. Net Loss.
As you might know, Alimera Sciences, Inc. (NASDAQ:ALIM) recently reported its yearly numbers. Sales of US$54m came in...
The amount of the new funding includes an initial tranche of $42.5 million used to repay the current facility, including principal, prepayment fees and accrued interest, and another $2.5 million tranche that will be available if Alimera achieves $30.0 million in revenue for any trailing six-month period ending on or before November 30, 2020. The interest-only period may be extended an additional six months if Alimera achieves $34.5 million in revenue for any trailing six-month period ending on or before June 30, 2022. “We are pleased that Solar Capital has agreed to extend our relationship and continue working with Alimera in support of our future growth,” said Rick Eiswirth, Alimera’s president and chief executive officer.
Ronald L Chez, a private investor, files a 13D for Alimera Sciences, Inc. (NASDAQ: ALIM). Alimera returns to growth in the 3rd quarter and expects continued progress in the 4th quarter. The Company is in a strong position to succeed with their unique approach to DME.
Alimera Sciences, Inc. (ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announces top-line revenue guidance for the quarter ended March 31, 2020. Alimera expects to report consolidated net revenue for the first quarter of 2020 exceeding $14 million, which compares to $12.9 million in the first quarter of 2019. Alimera expects to report cash on hand in excess of $12 million at March 31, 2020.
Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will report first quarter 2020 financial results on Wednesday, April 29, 2020 after the market close. scottg@coreir.com
First Quarter and Recent Company Highlights: Consolidated Net Revenue Up 12% Compared to First Quarter 2019International Net Revenue Up 23% Compared to First Quarter 2019Net.
Alimera Sciences, Inc. (NASDAQ:ALIM) shareholders (or potential shareholders) will be happy to see that insider Ronald...
ATLANTA, March 25, 2020 -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology.
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 44.19% and 3.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 121.62% and 19.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Q4 2019 Alimera Sciences Inc Earnings Call
Under the terms of the agreement, Alimera had the option to draw down an additional $2.5 million if it achieved $30.0 million in revenue for any trailing six-month period ending on or before November 30, 2020. The $2.5 million loan brings the total Alimera borrowings under the agreement to the maximum $45 million available. “We are pleased to draw these funds so quickly, as it reflects the continued strong growth of our ILUVIEN® franchise and will be added to our current cash on hand,” said Rick Eiswirth, Alimera’s president and chief executive officer.
Joining me from Alimera's leadership team today are Rick Eiswirth, President and Chief Executive Officer and Phil Jones, Chief Financial Officer. Thank you, Jules and good morning to everyone participating in today's call.
"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]